Abzena has released a new white paper exploring the critical factors that underpin the clinical success of bioconjugates, including antibody-drug conjugates (ADCs), peptide-drug conjugates, and conjugate vaccines.
The paper emphasises the importance of careful early-stage design and developability assessments to mitigate risks before entering the clinic. It also highlights Abzena’s proprietary ThioBridge™ technology, which enables stable, site-specific conjugation to improve the safety, efficacy, and consistency of ADCs compared to traditional methods.
Drawing on real-world expertise, the white paper includes a case study on ACT-903 – a novel AFP-maytansinoid conjugate that demonstrated potent anti-tumour activity and minimal off-target toxicity in pre-clinical models.
With its integrated services spanning antibody discovery, conjugation chemistry, process development, and cGMP manufacturing, Abzena supports the rapid advancement of complex therapeutic modalities from discovery to commercial production. This end-to-end capability helps reduce scientific and operational risk while accelerating timelines to clinical success.
Download the full white paper here to learn more
